Tests adebrelimab with chemoradiotherapy in locally advanced cervical cancer
Tests adebrelimab alongside chemoradiotherapy in adults with locally advanced cervical cancer.
Plain-language title generated from the registry record
Registry title: A Phase III Clinical Study of Adebrelimab Combined With Concurrent Chemoradiotherapy Versus Placebo Combined With Concurrent Chemoradiotherapy for the Treatment of Locally Advanced Cervical Cancer
Key facts
- Where
- Shanghai, ChinaSee the site
- Phase
- Phase 3
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 75 years old?
Source: NCT07168200, who can take part
Where in China
- Fudan University Shanghai Cancer CenterShanghai, ChinaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Shanghai Shengdi Pharmaceutical Co., Ltd
- Trial code
- NCT07168200
- Record updated
- 15 April 2026
- Original description
This study aims to evaluate the efficacy of Adebrelimab plus concurrent chemoradiotherapy compared with placebo plus concurrent chemoradiotherapy for the treatment of locally advanced cervical cancer by evaluating progression-free survival (PFS).Read full original descriptionShow less
A Randomized, Controlled, Double-blind, Multicenter Phase III Clinical Study of Adebrelimab Combined With Concurrent Chemoradiotherapy Versus Placebo Combined With Concurrent Chemoradiotherapy for the Treatment of Locally Advanced Cervical Cancer
This study aims to evaluate the efficacy of Adebrelimab plus concurrent chemoradiotherapy compared with placebo plus concurrent chemoradiotherapy for the treatment of locally advanced cervical cancer by evaluating progression-free survival (PFS).
Inclusion: Participate in the study voluntarily, sign the informed consent form; Subjects were able to provide primary or metastatic cancer samples; At least one measurable lesion; Expected survival > 3 months; ECOG 0 ~ 1; With adequate organ functions.
Exclusion: Administering live vaccines within 4 weeks before enrollment or during planned study treatment; Participants who received immunosuppressive therapy within 4 weeks before enrolment; For participants who are receiving thrombolytic/anticoagulant therapy, prophylactic anticoagulant therapy is allowed; Known allergy to the investigational drug or any of its excipients; or severe allergic reaction to other monoclonal antibodies; Pathologically or radiologically confirmed presence of distant metastatic disease, including lymph nodes above the first lumbar vertebra (L1) (cephalad) or in the inguinal region; Participants who have had other uncured malignant tumors in the past (within 5 years) or concurrently have had other uncured malignant tumors, excluding cured basal cell carcinoma of the skin and carcinoma in situ; According to the investigator's judgment, there are diseases or any other conditions that may seriously endanger the safety of the subjects, may confound the research results, or affect the subjects' ability to complete the study; Pregnant or breastfeeding women.